share_log

TC BioPharm | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-MEDINET Co., Ltd.(0.0%)

SEC announcement ·  Jan 29 09:18
Summary by Moomoo AI
MEDINET Co., Ltd., a Japanese company, has filed an amendment to Schedule 13G, indicating that as of December 31, 2023, they no longer beneficially own more than five percent of TC BioPharm (Holdings) plc's ordinary shares. The filing, dated January 29, 2024, specifies that MEDINET does not hold any voting or dispositive power over the shares of the Scotland-based biopharmaceutical company. The amendment to the Schedule 13G is a regulatory requirement under the Securities Exchange Act of 1934, and the filing indicates that the shares were not acquired for the purpose of changing or influencing the control of TC BioPharm, nor were they held in connection with any transaction with such purpose or effect.
MEDINET Co., Ltd., a Japanese company, has filed an amendment to Schedule 13G, indicating that as of December 31, 2023, they no longer beneficially own more than five percent of TC BioPharm (Holdings) plc's ordinary shares. The filing, dated January 29, 2024, specifies that MEDINET does not hold any voting or dispositive power over the shares of the Scotland-based biopharmaceutical company. The amendment to the Schedule 13G is a regulatory requirement under the Securities Exchange Act of 1934, and the filing indicates that the shares were not acquired for the purpose of changing or influencing the control of TC BioPharm, nor were they held in connection with any transaction with such purpose or effect.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more